CRISPR Therapeutics CRSP announced that it has entered into a collaboration deal with San Diego-based privately held company, Sirius Therapeutics, for developing and commercializing novel siRNA ...

The partnership with Sirius expands CRISPR Therapeutics’ modality toolkit, especially in the cardiovascular space.

-Under the agreement, CRISPR Therapeutics will make an upfront payment of $25 million in cash and $70 million in equity to ...

The strategic partnership is likely to diversify CRISPR Therapeutics’ pipeline by adding Sirius’s lead candidate, SRSD107, a next-generation, long-acting siRNA therapy, which is being ...

CRISPR Therapeutics is paying $25 million upfront to work on multiple siRNA targets with Sirius Tx with an early focus on the ...

CRISPR Therapeutics and Sirius Therapeutics have formed a strategic ... clinical trials and pipeline products and programs, including, without limitation, expectations regarding data, safety ...

Sirius Therapeutics today announced that it has ... this round will further advance our clinical programs and expand our pipeline, to deliver “transformative siRNA therapeutics for patients ...

CEO of Sirius Therapeutics. "We are deeply grateful to our new and existing investors for their continued support. The funds from this round will further advance our clinical programs and expand our ...

Sirius Therapeutics Inc. raised nearly $50 million in a series B2 financing round May 9 to support its pipeline of small interfering RNA (siRNA) molecules for cardiovascular disease indications.